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REVIEW
Abstract: Clinicians now have five oral antifungal therapeutic agents to choose from when
assessing the risk–benefits associated with a particular treatment for onychomycosis (OM):
griseofulvin, itraconazole, terbinafine, ketoconazole, and fluconazole. Only the first three are
approved by the FDA for this indication. Griseofulvin is fungistatic and inhibits nucleic acid
synthesis, arresting cell division at metaphase, and impairing fungal wall synthesis. Due to its
low cure rates and high relapse, it is rarely used for treatment of onychomycosis. Itraconazole
is a broad spectrum drug and is effective against dermatophytes, candida, and some non-
dermatophytic molds. Itraconazole works by inhibiting ergosterol synthesis via cytochrome
P-450 (CYP450)-dependent demethylation step. This azole antifungal agent is metabolized
in the liver by cytochrome P-450 3A4 (CYP3A4), and therefore has the potential to interact
with drugs metabolized through this pathway. Terbinafine, an allylamine, is fungicidal and
remains at therapeutic levels in keratinized tissues, but with a short plasma half-life of 36
hours. Terbinafine has the advantage in that it does not inhibit CYP3A4 isoenzyme during its
metabolism where some 50% of all commonly prescribed drugs are metabolized. The only
potentially significant drug interaction with terbinafine is with the cytochrome P-450 2D6
(CYP2D6) isoenzyme. The lack of widely reported or published clinically relevant drug
interactions, and extensive experience from a large prospective, surveillance study conducted
in “real world” setting with no patient exclusions, suggest that this is not a major issue. The
high cure rates of terbinafine against dermatophytes, as shown in many studies since its launch
in the 1990s, together with lack of clinically significant drug interactions and well established
safety record, indicate the use of continuous oral terbinafine as the top choice for the treatment
of onychomycosis in most patients.
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Introduction
Onychomycosis is relatively common, with a prevalence of 6.5%–6.8% in the general
population in Canada (Gupta et al 1997), 8.5% in the general male population in
Finland (Heikkila and Stubb 1995), and up to 18.5% in the US (Ghannoum et al
2004). Some studies suggest that as much as 48% of the population may be affected
by the age of 70 (Drake et al 1998; Scher 1999).
Balancing patient safety with therapeutic benefit is a prime directive when treating
onychomycosis. There are several oral antifungal agents to choose from when
assessing the risk–benefits associated with a particular treatment for onychomycosis;
griseofulvin, ketoconazole, fluconazole, itraconazole, and terbinafine, although only
three have been approved by the Food and Drug Administration (FDA). Fluconazole,
an azole much like itraconazole, can be used, but it is not approved for onychomycosis.
Ketoconazole is rarely used due to poor tolerability, low efficacy, and the availability
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of new antifungal agents. In this review, we compare the
mode of action, pharmacokinetics, and potential for drug
interactions for various oral antifungal agents. However,
the focus is on the mode of action, pharmokinetics,
tolerability, and safety of the three FDA approved oral drugs
griseofulvin, itraconazole, and terbinafine. An increased
understanding of the metabolism of all the oral antifungal
agents allows a better appreciation of potential drug–drug
interactions, impact on safety, and appropriate choice of
therapy. This is particularly relevant as the number of
patients on polypharmacy is increasing due to an aging
population and increased comorbidities. Moreover, the
widespread use of cholesterol-lowering statins and
antihypertensive drugs in otherwise healthy individuals may
put many patients at risk for drug interactions.
Pharmacokinetics
Mode of action
Griseofulvin acts by disrupting the fungal mitotic spindle,
inhibiting cell wall synthesis, whereas azoles act to block
ergosterol synthesis, required for assembly of the fungal
cell wall, by inhibiting C14α-demethylase, a member of
the cytochrome P-450 (CYP450) family. Terbinafine works
much like azoles, with the exception that it blocks ergosterol
synthesis further upstream by inhibiting squalene epoxidase.
This results in cells becoming deficient in ergosterol and
causes accumulation of toxic squalene, which, in turn, results
in fungal death. This activity makes terbinafine a fungicidal
drug compared with azoles which are fungistatic. This step
does not involve CYP450 enzymes, therefore drug inter-
actions are not typically an issue (Figure 1).
Absorption
Griseofulvin is poorly absorbed, unless micronized, or
coated with polyethylene glycol, or given with fatty meals
(Lin et al 1982). Its absorption decreases with repeated
administration, possibly due to damage to the mucosal wall
by unabsorbed griseofulvin (Debruyne and Coquerel 2001).
This agent has therefore largely been superceded by
compounds with better pharmacokinetics. The bio-
availability of the most effective azole antifungal,
itraconazole, is increased by coadministration of food, and
decreased in the presence of agents that reduce gastric
acidity, eg, antacids, H2 blocker antihistamines, proton
pump inhibitors, and the anti-HIV agent, oral didanosine.
The efficacy of itraconazole may therefore be compromised
by drug coadministration. The bioavailability of terbinafine
is good, with 70%–80% of the ingested dose being absorbed,
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Figure 1 Mode of action of allylamine and azole antifungal agents.
Table 1 Characteristics of oral antifungal agents
Route of
Metabolic incorporation Oral Spectrum
effect into nails absorption of activity Efficacy
Allylamines Accumulation of Via diffusion from Good absorption Broad Very high
(terbinafine) squalene (fungicidal); nail plate and nail unaffected by food or
depletion of ergosterol matrix drug coadministration
(fungistatic)
Triazoles (itraconazole,  Depletion of ergosterol Via diffusion from nail Absorption improved if Broad Intraconazole
fluconazole) (fungistatic) bed and nail matrix administered with food; more effective
absorption decreased if than fluconazole
coadministered with
agents that decrease
gastric acidity
Antibiotics Disruption of fungal Deposited in keratin Poorly absorbed but Narrow Low
(griseofulvin) mitotic spindle matrix precursor cells improved if
(fungicidal) administered with foodTherapeutics and Clinical Risk Management 2005:1(4) 301
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and maximal plasma concentrations reached within 8 hours
(Debruyne and Coquerel 2001). In addition, the absorption
of terbinafine is unaffected by coadministration of food or
agents that decrease gastric pH (Table 1).
Concentrations in the nails and plasma
Steady-state plasma levels of terbinafine are reached after
10–14 days of treatment (De Doncker 1997), and
itraconazole within 3 weeks (Leyden 1998). Both terbinafine
and itraconazole can be measured in the nail by 7 days after
the start of treatment, indicating that the route of entry into
the nail plate is via the nail bed and the matrix (De Doncker
1997), rather than solely by incorporation into keratin
precursor cells, as seen with griseofulvin (Debruyne and
Coquerel 2001). Terbinafine reaches a steady state in the
nail after 1 week of treatment, whereas itraconazole may
require 3–12 weeks; these levels are then sustained in the
nail plate for several months.
The older generation of antifungal drugs (eg,
griseofulvin) had to be used continuously until an entirely
new nail plate was grown out, which could take up to a
year. Griseofulvin has low affinity for keratins and drug
levels decline rapidly with plasma levels (Meinhof 1993).
Also, the drug persists for only a short duration, for
approximately two weeks after treatment is discontinued.
On the other hand, both itraconazole and terbinafine are
keratinophilic and lipophilic, allowing them to be used for
only a short period of time. Terbinafine can persist in the
nails between 24 and 156 days (Debruyne and Coquerel
2001); this allows terbinafine to be used effectively with
relatively short courses of treatment. Plasma levels of
terbinafine and itraconazole fall rapidly after the end of
treatment, and the shorter treatment requirements with both
drugs further minimize the likelihood of systemic side effects
(Debruyne and Coquerel 2001).
Drug interactions
Potential drug interactions that could reduce efficacy or drug
toxicity must be taken into account when assessing the
benefits and risks of the different oral antifungal agents.
The most common hepatic enzyme involved in drug
metabolism is cytochrome 3A4 (CYP3A4), which is
required for the clearance of many different therapeutic
agents.
Griseofulvin
Griseofulvin is not indicated for those with porphyria and
hepatocellular failure. Also, patients on warfarin-type
Table 2 Drug–drug interactions observed with azole
antifungal drugs and CYP3A4 metabolizing agents
Agent Indication
Contraindicated
Quinidine Antimalarial prophylaxis
Arrythymias
Selected benzodiazapines Anxiety
Pimozide Psychotic symptoms
Dofetilide Arrythmias
Lovastatin, simvastatin, High cholesterol, heart disease
atovastatin
Reported drug–drug interactions
Nifedipine Hypertension
Potential for drug–drug interactions
Phenytoin Epilepsy
Astemizole Allergy
Midazolam Anxiety
Oral contraceptives Contraception
Reaglinide, pioglitzone Diabetes
Cisapride Poor gastrointestinal motility
Didanosine HIV
Ritonavir, saquinavir, HIV
Amprenavir
Digoxin Congestive heart failure
H2 receptor blockers Dyspepsia, stomach ulcer
Isoniazid Tuberculosis
Rifampicin Tuberculosis
Tacrolimus Transplant recipients
Vincristine Solid tumors
Warfarin Anticoagulant
anticoagulants may need an adjustment of their anti-
coagulant dose (Develoux 2001). These may cause
contraceptive failure especially of low dose pills. The major
drug interactions noted are with phenobarbital, anti-
coagulants, and oral contraceptives.
Azole antifungal agents
These are metabolized in the liver by CYP3A4, and thus
have the potential to interact with a long list of clinically
important agents (Table 2). In particular, concurrent
administration of azole antifungal agents and the following
therapeutics are contraindicated: the antidysrhymic and
antimalarial agent, quinidine; benzodiapines that undergo
oxidative metabolism (including alprazolam, chlordia-
zepoxide, clonazepam, diazepam, estazolam, flurazepam,
halazepam, quazepam, and triazolam); dofetilide; the
antipsychotic, pimozide; and the statins, lovastatin,Therapeutics and Clinical Risk Management 2005:1(4) 302
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simvastatin, and atovastatin (Katz 1999; Shapiro and Shear
2002). Peripheral edema resulting from coadministration
of itraconazole and calcium channel blocker, nifedipine, has
also been reported (Tailor et al 1996).
Other commonly used agents that are metabolized by
CYP3A4 are warfarin, cisapride, and cyclosporine.
Monitoring of serum levels, and dosage adjustment if
indicated, should therefore be carried out during treatment
with itraconazole (Shapiro and Shear 2002). Inhibition of
CYP3A4 by itraconazole may increase warfarin’s anti-
coagulant activity when administered together (Del Rosso
2004). Similarly, some oral antidiabetic agents, including
reaglinide and pioglitzone, are metabolized by CYP3A4,
and concurrent administration may cause hypoglycemia (Del
Rosso 2004). Any agent that induces CYP3A4, such as
rifampicin and phenytoin, may increase the metabolism and
therefore reduce the efficacy of itraconazole (Shear et al
2000). Itraconazole levels should therefore be monitored in
the event of coadministration with these agents.
Azole antifungal agents have also been implicated in
several hormone–drug interactions (Venkatakrishnan et al
2000). Patients with HIV infection undergoing treatment
with highly active retroviral therapy are also likely to be
receiving protease inhibitors such as ritonavir, saquinavir,
or amprenavir that are potent inhibitors of CYP3A4. The
effects of ketoconazole on amprenavir and saquinavir have
been documented, and in the event of concurrent treatment
with azole antifungal agents and protease inhibitors, dose
reduction of the latter is required.
Terbinafine (allylamine)
In contrast with azole antifungal agents, the potential of
terbinafine for drug interaction is generally considered low.
Side effects associated with CYP3A4 are not observed.
While terbinafine is metabolized extensively in the liver,
this occurs via the action of various P-450 enzymes (eg,
CYP2C9, CYP1A2, CYP3A4, CYP2C8, and CYP2C19)
(Vickers et al 1999). In addition, metabolism of terbinafine
requires less than 5% of the total liver CYP450 capacity
(Vickers et al 1999). Clinically significant drug interactions
are limited to cimetidine and rifampicin, which decrease
and increase the rate of terbinafine plasma clearance,
respectively. The rate of clearance of terbinafine is reduced
by one-third in the presence of cimetidine, and doubles in
the presence of rifampicin (Shear et al 2000). Terbinafine
inhibits the cytochrome family member, cytochrome P-450
2D6 (CYP2D6) (Abdel-Rahman et al 1999), and caution
may be indicated when administering CYP2D6 substrates,
such as nortriptyline, desipramine, perphenazine,
metoprolol, encainide, and propafenone (Shear et al 2000;
Debruyne and Coquerel 2001). Concentrations of warfarin
may be altered when coadministered with terbinafine (Shear
et al 2000).
Terbinafine has a terminal half-life of 16–22 hours
(Debruyne and Coquerel 2001). This is prolonged in patients
with liver or kidney impairment, and patients with a
creatinine clearance less than 50 mL/min or serum creatinine
level of more than 300 µmol/L should receive half the normal
dose. Terbinafine is primarily excreted (> 70%) in the urine
(see Table 3) (Balfour and Faulds 1992).
Liver enzyme elevations
Despite transient asymptomatic liver enzyme changes seen
in clinical trials, terbinafine is not listed in the British
National Formulary as a potential inducer of liver enzymes.
While some rare cases of hepatic failure have been reported
among millions of adults treated for OM (van ‘t Wout et al
1994; Boldewijn et al 1996; Mallat et al 1997; Shiloah et al
1997; Vivas et al 1997; Gupta et al 1998; Anania and Rabin
2002), many of these patients were elderly and/or had
preexisting liver diseases; therefore the causal relationship
in many such cases has not been unequivocally determined.
The risk of acute liver injury among 69 830 patients
treated with oral antifungal agents was determined in a
cohort study in which patients with prior liver disease were
excluded (Garcia Rodriguez et al 1999). The incidence rates
of acute liver injury were found to be 134.1 per 100 000
person-months; (95% confidence interval [CI]: 36.8, 488.0)
for ketoconazole, 10.4 (95% CI: 2.9, 38.1) for itraconazole,
and 2.5 (95% CI: 0.4, 13.9) for terbinafine. Ketoconazole
was associated with the highest relative risk with 228.0 (95%
CI: 33.9, 933.0), when compared with the risk among non-
users, followed by itraconazole (relative risk [RR] 17.7; 95%
CI: 2.6, 72.6) and terbinafine (RR 4.2; 95% CI: 0.2, 24.9).
This cohort study confirms the finding that most case reports
of liver injury after administration of oral antifungal agents
occur with ketoconazole and itraconazole, and argues against
using these agents as initial treatment for uncomplicated
fungal infections. While the Rodriguez study (Garcia
Rodriguez et al 1999) highlights low incidence of liver injury
for terbinafine, the higher rates of hepatotoxicity seen with
azole antifungals has adversely affected the perception of
terbinafine-induced liver enzyme elevation. The incidence
of terbinafine-related hepatobiliary dysfunction in the same
studies are even lower at 1 in 45 000–120 000 patients (Hay
1993). To put this finding further into context, the low riskTherapeutics and Clinical Risk Management 2005:1(4) 303
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of hepatic injury observed with terbinafine may be
comparable to that seen with paracetamol, a medication
widely used for pain relief, and perceived as safe by the
general population (Friis and Andreasen 1992; Skorepova
2004).
The risk of hepatotoxicity with terbinafine should not
be exaggerated, but should be taken into account, together
with any other relevant factors. Patients with chronic or
active liver diseases should not be treated with terbinafine,
and baseline (pretreatment) liver transaminase testing is
recommended. While some physicians continue to monitor
liver enzymes during the course of terbinafine treatment,
this is no longer recommended by the revised current
labeling. After many years of experience with terbinafine,
the FDA subsequently removed the LFT monitoring
recommendation from the terbinafine label (MedWatch
2001). This is in line with early safety data reported for
1508 patients with toenail onychomycosis, with a mean age
of 50 years, and extensive intractable disease, averaging over
11 years in duration (Pollak and Billstein 1997). The
incidence of hepatic or biliary disorders was 2.8%, of which
the most common was abnormal liver function tests (2.4%).
A recent study of 504 patients, in which patients with
baseline abnormal liver enzymes were excluded, showed
no clinically significant alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) elevation in plasma levels
when tested 6 weeks into the treatment (250 mg/day) (Pollak
et al 2004). For griseofulvin, there is a clear dosage-
dependent association with hepatic toxicity, particularly in
patients with prior liver damage (Skorepova 2004).
Tolerability of oral antifungal
(adverse drug events)
Griseofulvin
Availability of newer antifungal agents terbinafine and
itraconazole suggest that griseofulvin is no longer the
treatment of choice for dermatophyte onychomycosis. Side-
effects include nausea and rashes in 8%–15% of patients.
In adults, it is contraindicated in pregnancy and the
Table 3 Randomized trials with terbinafine 250 mg daily
Mycological
Trial Subject Treatment cure rate
design (n) duration at study end Reference
Terbinafine 250 mg daily vs placebo Terbinafine Placebo
112 3 months 48% 13% Goodfield et  al 1992
111 3 months 59% 9% Watson et al 1995
358 3 and 6 months 70% and 87% 9% Drake et al 1997
Terbinafine 250 mg daily vs itraconazole
200 mg daily Terbinafine Itraconazole
195  3 months 78% 61% Brautigam et al 1995
372  3 months 73% 46% De Backer et al 1998
Continuous terbinafine 250 mg daily
vs intermittent itraconazole 400 mg daily
(LION Study) Terbinafine Itraconazole
496 Terbinafine daily for 76% (3 months) 38% (3 months) Evans and
3 or 4 months, or  and 81% and 49% Sigurgeirsson 1999
itraconazole 1 week (4 months) (4 months)
in every 4, for 3 or
4 months
Terbinafine vs griseofulvin Terbinafine Griseofulvin
195 24 weeks terbinafine 81% 62% Hofmann et al 1995
vs 24 weeks
griseofulvin
180 12 weeks 90% 64% Haneke et al 1995
Terbinafine 250 mg daily
vs fluconazole 150 mg daily Terbinafine Fluconazole
137 3 months terbinafine  88% 51% ( 3 months) Havu et al 2000
vs 3 or 6 months 49% (6 months)
fluconazole
Abbreviations: LION, lamisil vs itraconazole in onychomycosis.Therapeutics and Clinical Risk Management 2005:1(4) 304
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manufacturers caution against men fathering children for
6 months after therapy.
Terbinafine
Safety data from four large-scale post-marketing surveys
investigating safety of terbinafine in actual clinical practice
in an uncontrolled setting have been pooled and reported
(Hall et al 1997; O’Sullivan 1999). The incidence of adverse
events was 10.5%; the majority involved the gastrointestinal
system (4.9%) or skin (2.3%); these tended to be mild,
transient, and reversible. Terbinafine was considered a
“possible” or “probable” cause of only 11 (0.04%) serious
adverse events. No drug–drug interactions were reported,
even in patients taking oral antidiabetic agents (astemizole,
terfenadine, or cimetidine), nor were any previously
unrecognized risks identified.
In a post-marketing survey of terbinafine conducted in
1996, involving 10 000 patients, transient taste disturbance
was reported by 0.06% of patients (O’Sullivan et al 1996).
All patients with taste loss fully recovered the sensation, at
an average of 6 weeks (range 2–186 weeks) (O’Sullivan et
al 1996). As per terbinafine’s prescribing information, rare
incidence of cutaneous abnormalities (eg, Stevens-Johnson
syndrome or toxic epidermal necrolysis; Carstens et al 1994;
Todd et al 1995) have been reported. Over a period of
approximately 15 years, only two instances of longer-term
taste disturbance have been reported or reversible taste loss
or changes (Beutler et al 1993; Duxbury et al 2000).
The good safety profile has been reported in elderly and
diabetic patients in early studies (Nedelman et al 1997;
Pollak and Billstein 1997; Smith et al 2000; Elewski and
Smith 2001). Good safety results have also been obtained
in other special patient populations (Cribier and Bakshi
2004; Gupta et al 2005).
In a study by Pollak and Billstein (1997), comparable
numbers of patients received 12, 18, and 24 weeks of
250 mg/day terbinafine. No serious adverse events
considered to be related to the study drug were reported,
either in the intent to treat population as a whole, in those
over 60 years (n = 416), or in those with diabetes (n = 77).
The most prevalent adverse event (12.3% of patients) was
skin-related, most commonly a skin rash or nail disorder.
Gastrointestinal complaints (nausea, diarrhea, dyspepsia,
and abdominal pain) were recorded in 11.5% of patients,
with 3.9% considered to have a relationship with the study
drug. In a group of 30 patients aged over 60 years who
received 12 weeks of treatment, no serious adverse events
occurred (Smith et al 2000). Use of concomitant medications
was widespread, with 93.3% of patients receiving at least
one prescription or over-the-counter medication during
terbinafine treatment, and 27% receiving medications with
known interactions with azole antifungals. Although 16
patients used medications metabolized by CYP2D6, no drug
interactions occurred between these agents and terbinafine,
and no clinical consequences were seen (Smith et al 2000).
HIV patients are also at increased risk for drug
interactions, due to compromised liver function and low
white cell count (Elewski and Smith 2001). No drug
interactions have been observed during terbinafine treatment
of fungal infection (onychomycosis, tinea pedis, tinea cruris,
tinea corporis) in 57 patients with HIV infection (Nandwani
et al 1996; Herranz et al 1997; Rich et al 2001; Smith et al
2001). Although patient numbers are small, there was no
evidence of neutropenia, and no detrimental effect on liver
function even in patients with serological evidence of viral
hepatitis infection. In a subanalysis of 77 patients with
diabetes included in an open-label study, the safety profile
did not differ from that observed in the general population
(Pollak and Billstein 1997). Similarly, no drug interactions
were reported in a post-marketing survey in which 3.2% of
the 25 884 patients were diabetic (Hall et al 1997). In
addition, control of glucose levels remained unaltered during
12 weeks of terbinafine treatment in 89 patients with
diabetes, and no drug interactions or hypoglycemic episodes
were seen (Cribier and Bakshi 2004; Gupta et al 2005).
Itraconazole
Overall, itraconazole is well tolerated, with adverse effects
reported in approximately 3% of patients (Scher 1999). The
more common adverse effects are headache and
gastrointestinal symptoms such as diarrhea, dyspepsia,
abdominal pain, constipation, nausea, and flatulence, and
dermatologic symptoms such as rash, pruritus, and urticaria.
Acute generalized exanthematous pustulosis is associated
with both oral itraconazole and terbinafine and has been
rarely reported in the literature (Park et al 1997; Hall and
Tate 2000). In most cases, there are nearly complete
resolution of the pustular eruption within a few weeks
following cessation of drugs and treatment with topical and
systemic corticosteroids (Hall and Tate 2000). Liver enzyme
elevations, reported in 0.3%–0.5% of patients receiving
itraconazole therapy (Gupta and Shear 2000). Also, azoles
are potent inhibitors of vitanovir, saquinavir, and abacavir
and not recommended for this patient population.Therapeutics and Clinical Risk Management 2005:1(4) 305
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Approximately 26% of diabetic patients have
onychomycosis, and, compared with nondiabetics, this
patient population is at increased risk of secondary
complications, including onychocryptosis, bacterial
cellulitis, osteomyelitis, gangrene, or foot ulcers (Elewski
and Smith 2001). Effective treatment that does not interact
with oral hypoglycemic or cardiovascular agents, or worsen
glycemic control, is therefore of high importance. Azole
antifungal agents are not desirable under such a setting.
Conclusions
Both direct and historical comparison of griseofulvin with
studies of the newer antifungal agents terbinafine and
itraconazole suggest that griseofulvin is no longer the
treatment of choice for dermatophyte onychomycosis. While
itraconazole has been used for years with varying success,
its major drawback is the high potential for drug interactions.
This is particularly relevant since it is a potent inhibitor of
CYP3A4 and cannot be conveniently used with statins,
antidiabetics, or antihypertensives.
The potential for drug–drug interactions is low with oral
terbinafine, and this agent provides a viable treatment option
for elderly, diabetics, and immunocompromised patients
with HIV, who are likely to be receiving concomitant
medication. Moreover, due to the increasing use of
cholesterol lowering statins and antihypertensive drugs,
many otherwise healthy individuals may become at risk for
drug interactions. Terbinafine does not interact with these
classes of drugs.
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